Deal Description: Dec. 15, 2016 – Femasys Inc., a developer of innovative medical devices for the women's healthcare market, closed a $40 million in Series C financing. The transaction was arranged by Salem Partners, a Los Angeles-based investment bank which also participated as a principal investor. The Series C syndicate included multiple institutional investors, family offices and a multibillion-dollar global medical device company.
The funding will be used primarily to support the pivotal testing of FemBloc™, the Company's revolutionary, non-surgical permanent contraception solution. Femasys designed FemBloc to provide women with the first non-surgical permanent contraceptive option delivered exclusively in the physician's office.
Baker Botts was counsel to the investors in this transaction.
Client: Investors (Salem Partners, as arranger and lead investor, and a syndicate that included multiple institutional investors, family offices and a multibillion-dollar global medical device company)
Outside Counsel to Investors: Baker Botts L.L.P.
Other Parties: Femasys Inc.
Outside Counsel to Femasys Inc.: Dechert LLP
Value: $40 million
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of approximately 725 lawyers practicing throughout a network of 14 offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy and technology sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.